DWTXHealthcare · BiotechnologyDWTX Stock Forecast: Dogwood Therapeutics, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Dogwood Therapeutics, Inc. hold a median 12-month price target of $15 — +777.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 1 Aug 2026 — in the upper half.
DWTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Dogwood Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (81): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Dogwood Therapeutics, Inc. — and when they’d sell — is the membership.
DWTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DWTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +777.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Apr 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DWTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Dogwood Therapeutics, Inc. (DWTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.4×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- −1.5×
Cheaper than 70% of US stocks
Cheaper than 81% of US stocks
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −34.7%
- Return on assets
- −18.6%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
DWTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DWTX appears on the weeks it earns a place.
Frequently asked questions about DWTX stock
What is the DWTX stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Dogwood Therapeutics, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DWTX stock a buy right now?
Of the 2 analysts covering Dogwood Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dogwood Therapeutics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DWTX?
As at 1 Aug 2026, Dogwood Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).
Will DWTX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +777.2% from the last close, and Ticker Nerd's factor model ranks Dogwood Therapeutics, Inc. 53 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DWTX stock forecast for 2030?
No analyst covering Dogwood Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.
How has DWTX stock performed over the past year?
Dogwood Therapeutics, Inc. returned -64.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Dogwood Therapeutics, Inc. do?
Dogwood Therapeutics Inc. is a biopharmaceutical company engaged in the research and development of innovative drug therapies to address unmet medical needs.
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics Inc. is a biopharmaceutical company engaged in the research and development of innovative drug therapies to address unmet medical needs. The company focuses primarily on the development of novel treatments for rare diseases, leveraging cutting-edge technologies and proprietary platforms. Dogwood Therapeutics aims to bring transformative solutions to patients with limited treatment options, working closely with scientific communities and regulatory bodies to advance its clinical programs. With a robust pipeline of candidates in various stages of clinical trials, the company plays a significant role in the biotechnology industry, contributing to the advancement of medical science and therapeutic innovations. Dogwood Therapeutics strategically collaborates with academic institutions and pharmaceutical companies to enhance its research capabilities and accelerate the development process. In the financial market, the company’s performance is closely monitored by investors keen on the growth potential of its groundbreaking therapies and the impact on healthcare improvements. Dogwood Therapeutics Inc.'s commitment to addressing challenging health conditions underscores its importance in the broader pharmaceutical sector.
CEO Mr. Gregory Duncan · 8 employees · United States · https://dwtx.com